IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v12y2021i1d10.1038_s41467-021-22177-1.html
   My bibliography  Save this article

Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial

Author

Listed:
  • Prasanna Jagannathan

    (Stanford University
    Stanford University)

  • Jason R. Andrews

    (Stanford University)

  • Hector Bonilla

    (Stanford University)

  • Haley Hedlin

    (Stanford University)

  • Karen B. Jacobson

    (Stanford University)

  • Vidhya Balasubramanian

    (Stanford University)

  • Natasha Purington

    (Stanford University)

  • Savita Kamble

    (Stanford University)

  • Christiaan R. Vries

    (Stanford University)

  • Orlando Quintero

    (Stanford University)

  • Kent Feng

    (Stanford University)

  • Catherine Ley

    (Stanford University)

  • Dean Winslow

    (Stanford University)

  • Jennifer Newberry

    (Stanford University)

  • Karlie Edwards

    (Stanford University)

  • Colin Hislop

    (Stanford University)

  • Ingrid Choong

    (Stanford University)

  • Yvonne Maldonado

    (Eiger BioPharmaceuticals)

  • Jeffrey Glenn

    (Stanford University
    Stanford University)

  • Ami Bhatt

    (Stanford University
    Stanford University)

  • Catherine Blish

    (Stanford University)

  • Taia Wang

    (Stanford University
    Stanford University)

  • Chaitan Khosla

    (Stanford University)

  • Benjamin A. Pinsky

    (Stanford University
    Stanford University)

  • Manisha Desai

    (Stanford University)

  • Julie Parsonnet

    (Stanford University)

  • Upinder Singh

    (Stanford University
    Stanford University)

Abstract

Type III interferons have been touted as promising therapeutics in outpatients with coronavirus disease 2019 (COVID-19). We conducted a randomized, single-blind, placebo-controlled trial (NCT04331899) in 120 outpatients with mild to moderate COVID-19 to determine whether a single, 180 mcg subcutaneous dose of Peginterferon Lambda-1a (Lambda) within 72 hours of diagnosis could shorten the duration of viral shedding (primary endpoint) or symptoms (secondary endpoint). In both the 60 patients receiving Lambda and 60 receiving placebo, the median time to cessation of viral shedding was 7 days (hazard ratio [HR] = 0.81; 95% confidence interval [CI] 0.56 to 1.19). Symptoms resolved in 8 and 9 days in Lambda and placebo, respectively, and symptom duration did not differ significantly between groups (HR 0.94; 95% CI 0.64 to 1.39). Both Lambda and placebo were well-tolerated, though liver transaminase elevations were more common in the Lambda vs. placebo arm (15/60 vs 5/60; p = 0.027). In this study, a single dose of subcutaneous Peginterferon Lambda-1a neither shortened the duration of SARS-CoV-2 viral shedding nor improved symptoms in outpatients with uncomplicated COVID-19.

Suggested Citation

  • Prasanna Jagannathan & Jason R. Andrews & Hector Bonilla & Haley Hedlin & Karen B. Jacobson & Vidhya Balasubramanian & Natasha Purington & Savita Kamble & Christiaan R. Vries & Orlando Quintero & Kent, 2021. "Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial," Nature Communications, Nature, vol. 12(1), pages 1-10, December.
    • Handle: RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-22177-1
    DOI: 10.1038/s41467-021-22177-1
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-021-22177-1
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-021-22177-1?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-22177-1. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.